Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI

Background Glycoprotein IIb/IIIa receptor antagonists have been shown to have an impact on the outcomes of death/myocardial infarction (MI) in patients undergoing percutaneous coronary intervention. At our institution, tirofiban has largely replaced abciximab in an attempt to decrease costs. Objecti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Annals of pharmacotherapy 2003-10, Vol.37 (10), p.1375-1380
Hauptverfasser:	Dobesh, Paul P, Lanfear, Sara L, Abu-Shanab, Joy R, Lakamp, Jonathan E, Gowda, Siddhesh, Haikal, Maged Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Angioplasty, Balloon, Coronary Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Biological and medical sciences Cardiovascular system Female Humans Immunoglobulin Fab Fragments - administration & dosage Immunoglobulin Fab Fragments - economics Immunoglobulin Fab Fragments - therapeutic use Male Medical sciences Middle Aged Miscellaneous Myocardial Infarction - mortality Myocardial Infarction - therapy Pharmacology. Drug treatments Platelet Glycoprotein GPIIb-IIIa Complex - administration & dosage Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use Retrospective Studies Treatment Outcome Tyrosine - administration & dosage Tyrosine - adverse effects Tyrosine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!